The Association Between Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance T1 Mapping and Myocardial Dysfunction in Diabetic Rabbits

Overview

Journal Sci Rep

Specialty Science

Date 2017 Mar 25

PMID 28338005

Citations 8

Authors

Mu Zeng

Yingyan Qiao

Zhaoying Wen

Jun Liu

Enhua Xiao

Changlian Tan

Yibin Xie

Jing An

Zishu Zhang

Zhanming Fan

Debiao Li

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to assess the relationship between imaging surrogates for diffuse fibrosis and myocardial dysfunction. Thirty-six New Zealand white rabbits were classified into two groups: a control group (n = 18) and an alloxan-induced diabetes mellitus (DM) group (n = 18). For all rabbits, conventional ultrasonography, two-dimensional speckle tracking, and cardiac magnetic resonance (CMR) T1 mapping were performed; all of the rabbits were then sacrificed for Masson's staining. The extracellular volume (ECV) was calculated from pre- and post-contrast T1 values and compared with myocardial function measured by echocardiography using Pearson's correlation. In the DM group, ECV increased as the duration of diabetes increased, consistent with the changes in myocardial fibrosis verified by pathology. Moreover, ECV was strongly correlated with the early diastolic strain rate (r = -0.782, p < 0.001) and moderately correlated with the radial systolic peak strain (r = 0.478, p = 0.045). Thus, ECV is an effective surrogate for myocardial diffuse fibrosis on CMR imaging, and higher ECV values are associated with an increased impairment of myocardial diastolic function.

Citing Articles

Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.

Wang D, Naumova A, Isquith D, Sapp J, Huynh K, Tucker I Cardiovasc Diabetol. 2024; 23(1):197.

PMID: 38849829 PMC: 11161924. DOI: 10.1186/s12933-024-02294-z.

Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure.

Wang D, Naumova A, Isquith D, Sapp J, Huynh K, Tucker I Res Sq. 2024; .

PMID: 38585865 PMC: 10996801. DOI: 10.21203/rs.3.rs-4132581/v1.

Dynamic changes in cardiac morphology, function, and diffuse myocardial fibrosis duration of diabetes in type 1 and type 2 diabetic mice models using 7.0 T CMR and echocardiography.

Zhang H, Shi C, Liu D, Gao H, Zhao Q, Zhang N Front Endocrinol (Lausanne). 2023; 14:1278619.

PMID: 38027188 PMC: 10663371. DOI: 10.3389/fendo.2023.1278619.

Diabetic cardiomyopathy: Clinical phenotype and practice.

Zhao X, Liu S, Wang X, Chen Y, Pang P, Yang Q Front Endocrinol (Lausanne). 2022; 13:1032268.

PMID: 36568097 PMC: 9767955. DOI: 10.3389/fendo.2022.1032268.

Importance of cardiac imaging assessment of epicardial adipose tissue after a first episode of myocardial infarction.

Islas F, Gutierrez E, Cachofeiro V, Martinez-Martinez E, Marin G, Olmos C Front Cardiovasc Med. 2022; 9:995367.

PMID: 36451918 PMC: 9702512. DOI: 10.3389/fcvm.2022.995367.

References

Robins S . Biochemistry and functional significance of collagen cross-linking. Biochem Soc Trans. 2007; 35(Pt 5):849-52. DOI: 10.1042/BST0350849. View

Chin C, Semple S, Malley T, White A, Mirsadraee S, Weale P . Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging. 2013; 15(5):556-65. PMC: 3979453. DOI: 10.1093/ehjci/jet245. View

Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley C . T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson. 2012; 14:26. PMC: 3405486. DOI: 10.1186/1532-429X-14-26. View

Flett A, Sado D, Quarta G, Mirabel M, Pellerin D, Herrey A . Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2012; 13(10):819-26. DOI: 10.1093/ehjci/jes102. View

Dandamudi S, Slusser J, Mahoney D, Redfield M, Rodeheffer R, Chen H . The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail. 2014; 20(5):304-9. PMC: 4076144. DOI: 10.1016/j.cardfail.2014.02.007. View

Coelho-Filho O, Shah R, Mitchell R, Neilan T, Moreno Jr H, Simonson B . Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling. Circulation. 2013; 128(11):1225-33. PMC: 5308548. DOI: 10.1161/CIRCULATIONAHA.112.000438. View

Shivu G, Phan T, Abozguia K, Ahmed I, Wagenmakers A, Henning A . Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus. Circulation. 2010; 121(10):1209-15. DOI: 10.1161/CIRCULATIONAHA.109.873273. View

Aneja A, Tang W, Bansilal S, Garcia M, Farkouh M . Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008; 121(9):748-57. DOI: 10.1016/j.amjmed.2008.03.046. View

Wei Z, Zhang H, Su H, Zhu T, Zhu Y, Zhang J . Correlation between myocardial dysfunction and perfusion impairment in diabetic rats with velocity vector imaging and myocardial contrast echocardiography. Echocardiography. 2012; 29(10):1247-55. DOI: 10.1111/j.1540-8175.2012.01796.x. View

10.

Muranaka A, Yuda S, Tsuchihashi K, Hashimoto A, Nakata T, Miura T . Quantitative assessment of left ventricular and left atrial functions by strain rate imaging in diabetic patients with and without hypertension. Echocardiography. 2008; 26(3):262-71. DOI: 10.1111/j.1540-8175.2008.00805.x. View

11.

van Heerebeek L, Hamdani N, Handoko M, Falcao-Pires I, Musters R, Kupreishvili K . Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2007; 117(1):43-51. DOI: 10.1161/CIRCULATIONAHA.107.728550. View

12.

Lee S, Lee W, Lee J, Park E, Kim H, Kim Y . Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology. 2014; 274(2):359-69. DOI: 10.1148/radiol.14141120. View

13.

Mir S, Darzi M . Histopathological abnormalities of prolonged alloxan-induced diabetes mellitus in rabbits. Int J Exp Pathol. 2009; 90(1):66-73. PMC: 2669619. DOI: 10.1111/j.1365-2613.2008.00615.x. View

14.

Tan S, Zhang Y, Wang B, Tan C, Zammit S, Williams S . FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. Clin Exp Pharmacol Physiol. 2012; 39(8):650-6. DOI: 10.1111/j.1440-1681.2012.05726.x. View

15.

Nenna A, Nappi F, Avtaar Singh S, Sutherland F, Di Domenico F, Chello M . Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Res Cardiovasc Med. 2015; 4(2):e26949. PMC: 4571620. DOI: 10.5812/cardiovascmed.4(2)2015.26949. View

16.

Shao C, Rozanski G, Patel K, Bidasee K . Dyssynchronous (non-uniform) Ca2+ release in myocytes from streptozotocin-induced diabetic rats. J Mol Cell Cardiol. 2006; 42(1):234-46. DOI: 10.1016/j.yjmcc.2006.08.018. View

17.

Sveen K, Nerdrum T, Hanssen K, Brekke M, Torjesen P, Strauch C . Impaired left ventricular function and myocardial blood flow reserve in patients with long-term type 1 diabetes and no significant coronary artery disease: associations with protein glycation. Diab Vasc Dis Res. 2014; 11(2):84-91. DOI: 10.1177/1479164113518805. View

18.

Kosmala W, Przewlocka-Kosmala M, Wojnalowicz A, Mysiak A, Marwick T . Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction. Eur Heart J Cardiovasc Imaging. 2011; 13(6):459-67. DOI: 10.1093/ejechocard/jer291. View

19.

De Meester de Ravenstein C, Bouzin C, Lazam S, Boulif J, Amzulescu M, Melchior J . Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn Reson. 2015; 17:48. PMC: 4464705. DOI: 10.1186/s12968-015-0150-0. View

20.

Huynh K, Kiriazis H, Du X, Love J, Gray S, Jandeleit-Dahm K . Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med. 2013; 60:307-17. DOI: 10.1016/j.freeradbiomed.2013.02.021. View